罗欣药业(002793) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss of between RMB 78.5 million and RMB 98.5 million for the fiscal year 2024, compared to a net loss of RMB 66.11 million in the same period last year[3] - The net profit after deducting non-recurring gains and losses is projected to be a loss of between RMB 62 million and RMB 82 million, slightly improved from a loss of RMB 63.89 million in the previous year[3] - Basic earnings per share are expected to be a loss of between RMB 0.74 and RMB 0.92, compared to a loss of RMB 0.61 per share last year[3] Business Development - The company has made significant progress in the hospital access work for its innovative drug, Tegolix, and has successfully obtained approval for new indications[5] - Increased marketing investments have been made to enhance brand and product recognition, aiming to build trust among doctors and patients for future market share expansion[5] Subsidiary Performance - The company transferred 70% of the equity of its subsidiary, Shandong Luoxin Pharmaceutical Group Co., Ltd., to Shanghai Pharmaceutical Luoxin, with performance commitments affecting future payments[6] - The performance completion rate for the subsidiary in 2023 was 95.76%, but the business faces pressure in 2024 due to market changes and industry policy adjustments[6] Asset Management - The company has recognized impairment losses on certain assets based on prudence and market conditions, in accordance with accounting standards[6] Financial Reporting - The financial data presented is a preliminary estimate and has not been audited, with final figures to be confirmed in the annual report[7] - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the financial estimates[7]